Trinity Biotech Plc (TRIB)

$1.58

+0.01

(+0.64%)

Market is closed - opens 7 PM, 20 May 2024

Insights on Trinity Biotech Plc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 14.67M → 13.42M (in $), with an average decrease of 4.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -6.72M → -5.50M (in $), with an average increase of 11.1% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 21.7% return, outperforming this stock by 89.7%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 1.5% return, outperforming this stock by 91.8%

Performance

  • $1.58
    $1.61
    $1.58
    downward going graph

    0.0%

    Downside

    Day's Volatility :1.86%

    Upside

    1.86%

    downward going graph
  • $1.49
    $5.50
    $1.58
    downward going graph

    5.7%

    Downside

    52 Weeks Volatility :72.91%

    Upside

    71.27%

    downward going graph

Returns

PeriodTrinity Biotech PlcIndex (Russel 2000)
3 Months
-39.15%
0.0%
6 Months
-17.91%
0.0%
1 Year
-67.96%
-0.3%
3 Years
-90.28%
-20.6%

Highlights

Market Capitalization
14.5M
Book Value
- $3.12
Earnings Per Share (EPS)
-4.8
PEG Ratio
1.3
Wall Street Target Price
3.0
Profit Margin
-42.26%
Operating Margin TTM
-25.98%
Return On Assets TTM
-13.26%
Return On Equity TTM
-1913.45%
Revenue TTM
56.8M
Revenue Per Share TTM
7.42
Quarterly Revenue Growth YOY
-25.6%
Gross Profit TTM
38.1M
EBITDA
-14.3M
Diluted Eps TTM
-4.8
Quarterly Earnings Growth YOY
-0.77
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Trinity Biotech Plc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 89.87%

Current $1.58
Target $3.00

Company Financials

FY18Y/Y Change
Revenue
97.0M
↓ 2.12%
Net Income
2.4M
↓ 105.93%
Net Profit Margin
2.46%
↑ 43.08%
FY19Y/Y Change
Revenue
90.4M
↓ 6.8%
Net Income
-4.1M
↓ 270.13%
Net Profit Margin
-4.5%
↓ 6.96%
FY20Y/Y Change
Revenue
102.0M
↑ 12.77%
Net Income
-6.0M
↑ 47.88%
Net Profit Margin
-5.9%
↓ 1.4%
FY21Y/Y Change
Revenue
93.0M
↓ 8.84%
Net Income
875.0K
↓ 114.55%
Net Profit Margin
0.94%
↑ 6.84%
FY22Y/Y Change
Revenue
74.8M
↓ 19.56%
Net Income
-41.0M
↓ 4785.94%
Net Profit Margin
-54.83%
↓ 55.77%
FY23Y/Y Change
Revenue
56.8M
↓ 24.0%
Net Income
-24.0M
↓ 41.42%
Net Profit Margin
-42.26%
↑ 12.57%
Q4 FY22Q/Q Change
Revenue
14.8M
↓ 17.78%
Net Income
-6.3M
↓ 37.43%
Net Profit Margin
-42.52%
↑ 13.35%
Q1 FY23Q/Q Change
Revenue
18.0M
↑ 21.63%
Net Income
-10.1M
↑ 59.81%
Net Profit Margin
-55.87%
↓ 13.35%
Q2 FY23Q/Q Change
Revenue
13.9M
↓ 22.94%
Net Income
-6.0M
↓ 40.57%
Net Profit Margin
-43.09%
↑ 12.78%
Q3 FY23Q/Q Change
Revenue
14.7M
↑ 5.61%
Net Income
-6.7M
↑ 12.24%
Net Profit Margin
-45.79%
↓ 2.7%
Q4 FY23Q/Q Change
Revenue
13.4M
↓ 8.51%
Net Income
-5.5M
↓ 18.14%
Net Profit Margin
-40.97%
↑ 4.82%
Q1 FY24Q/Q Change
Revenue
13.4M
↑ 0.0%
Net Income
-5.5M
↑ 0.0%
Net Profit Margin
-40.97%
↑ 0.0%
FY18Y/Y Change
Total Assets
151.2M
↓ 21.48%
Total Liabilities
107.2M
↓ 15.88%
FY19Y/Y Change
Total Assets
131.1M
↓ 13.33%
Total Liabilities
126.4M
↑ 17.89%
FY20Y/Y Change
Total Assets
130.4M
↓ 0.51%
Total Liabilities
132.6M
↑ 4.95%
FY21Y/Y Change
Total Assets
118.9M
↓ 8.82%
Total Liabilities
119.2M
↓ 10.11%
FY22Y/Y Change
Total Assets
92.1M
↓ 22.53%
Total Liabilities
94.3M
↓ 20.92%
FY23Y/Y Change
Total Assets
59.4M
↓ 35.47%
Total Liabilities
83.4M
↓ 11.56%
Q4 FY22Q/Q Change
Total Assets
91.2M
↓ 1.03%
Total Liabilities
97.8M
↑ 3.71%
Q1 FY23Q/Q Change
Total Assets
92.1M
↑ 1.04%
Total Liabilities
94.3M
↓ 3.57%
Q2 FY23Q/Q Change
Total Assets
72.0M
↓ 21.84%
Total Liabilities
83.4M
↓ 11.57%
Q3 FY23Q/Q Change
Total Assets
63.6M
↓ 11.66%
Total Liabilities
81.1M
↓ 2.74%
Q4 FY23Q/Q Change
Total Assets
59.4M
↓ 6.54%
Total Liabilities
83.4M
↑ 2.84%
Q1 FY24Q/Q Change
Total Assets
59.4M
↑ 0.0%
Total Liabilities
83.4M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
6.9M
↓ 42.74%
Investing Cash Flow
-17.4M
↑ 7.48%
Financing Cash Flow
-17.0M
↑ 11.37%
FY19Y/Y Change
Operating Cash Flow
5.5M
↓ 21.07%
Investing Cash Flow
-11.9M
↓ 31.84%
Financing Cash Flow
-4.0M
↓ 76.47%
FY20Y/Y Change
Operating Cash Flow
23.8M
↑ 333.96%
Investing Cash Flow
-10.2M
↓ 13.96%
Financing Cash Flow
-2.7M
↓ 32.03%
FY21Y/Y Change
Operating Cash Flow
13.2M
↓ 44.27%
Investing Cash Flow
-7.1M
↓ 30.68%
Financing Cash Flow
-6.0M
↑ 121.61%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.7M
↓ 219.47%
Investing Cash Flow
-1.3M
↑ 0.38%
Financing Cash Flow
1.6M
↓ 187.15%
Q1 FY23Q/Q Change
Operating Cash Flow
2.3M
↓ 183.7%
Investing Cash Flow
-1.3M
↑ 0.0%
Financing Cash Flow
-1.8M
↓ 214.74%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.4M
↓ 294.2%
Investing Cash Flow
27.9M
↓ 2196.46%
Financing Cash Flow
-13.5M
↑ 629.21%

Technicals Summary

Sell

Neutral

Buy

Trinity Biotech Plc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Trinity Biotech Plc
Trinity Biotech Plc
-14.67%
-17.91%
-67.96%
-90.28%
-86.92%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
13.11%
16.66%
11.05%
3.31%
116.76%
Agilent Technologies Inc.
Agilent Technologies Inc.
14.69%
36.38%
20.77%
18.6%
123.28%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
9.12%
28.03%
14.47%
31.84%
128.15%
Danaher Corp.
Danaher Corp.
10.63%
27.46%
17.58%
5.55%
102.01%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
3.41%
14.75%
21.73%
1.52%
75.81%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Trinity Biotech Plc
Trinity Biotech Plc
NA
NA
1.3
0.0
-19.13
-0.13
NA
-3.12
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
53.2
53.2
4.75
11.04
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
36.86
36.86
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
38.47
38.47
2.81
21.71
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
47.66
47.66
3.13
7.61
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.15
32.15
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Trinity Biotech Plc
Trinity Biotech Plc
Buy
$14.5M
-86.92%
NA
-42.26%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$45.3B
116.76%
53.2
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$45.2B
123.28%
36.86
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$228.7B
128.15%
38.47
14.2%
Danaher Corp.
Danaher Corp.
Buy
$192.0B
102.01%
47.66
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.8B
75.81%
32.15
9.01%

Institutional Holdings

  • Hunter Associates Inc.

    4.26%
  • Stonehill Capital Management LLC

    3.96%
  • Renaissance Technologies Corp

    3.54%
  • Acadian Asset Management LLC

    1.79%
  • Whitefort Capital Management, LP.

    1.07%
  • CAMBRIDGE Invest RESEARCH ADVISORS, INC.

    0.29%

Company Information

since its formation in 1992, trinity biotech has actively pursued the aim of becoming a leading player in the international diagnostics industry. through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products. the test kits manufactured by trinity biotech are used in the clinical laboratory and point-of-care segments of the diagnostic market to detect infectious diseases, sexually transmitted diseases, autoimmune and haemoglobin disorders, and detect, monitor and control diabetes. the company is also a significant provider of raw materials to the life sciences industry. trinity biotech, which has its headquarters in ireland, employs in excess of 350 people and markets its portfolio of over 400 products to customers in 80 countries around the world. it reaches this worldwide market by combining the

Organization
Trinity Biotech Plc
Employees
380
CEO
Mr. John Gillard
Industry
Health Technology

FAQs